Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics and Abbott Enter Broad Drug-Discovery Collaboration

NEW YORK, April 11 (GenomeWeb News) - Myriad Genetics and Abbott said today that they have entered into a "broad drug-discovery collaboration" to identify unspecified therapeutic targets of interest.

 

The five-year research agreement calls for Myriad to use its RNA expression profiling and "other technologies" to identify human genes and regulatory networks associated with a variety of diseases, the companies said.

 

Abbott will then advance these genes through to its chemical genomics platform to identify targets and leads for drug discovery.

 

Each company will have exclusive rights to the therapeutic targets and drug lead compounds, with Myriad receiving rights to approximately 40 percent of the targets, and Abbott receiving rights to approximately 60 percent, the companies said.

 

It is unclear whether the new collaboration is related to a pharmacogenomics collaboration started between the companies in January 2004, and extended in November 2005.

 

Myriad and Abbott officials could not be reached for comment.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.